Aurobindo, INE406A01037

Aurobindo Pharma stock faces OAI finding at Lannett facility

Published on 11/20/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Aurobindo Pharma stock follows a US FDA finding at a Lannett facility. The company said the classification has no quantifiable financial or operational impact.

Key points

  • The US FDA classified an inspection at Aurobindo Pharma's Lannett facility as Official Action Indicated.
  • Aurobindo Pharma said the classification has no quantifiable financial or operational impact.
Aurobindo, INE406A01037, Illustration mit AI erstellt.

Aurobindo Pharma said on November 11, 2026, that the US Food and Drug Administration classified an inspection at its Lannett facility as Official Action Indicated. The company said the classification has no quantifiable financial or operational impact, according to an Alfa Finder summary of the NSE filing.

Regulatory update at Lannett

Official Action Indicated is a US FDA inspection classification that signals regulatory follow-up at the facility. Aurobindo's statement, as summarized in the filing report, did not quantify a financial or operational effect from the classification.

The update adds a regulatory consideration to the integration of Lannett, which Aurobindo completed as part of its expansion in the US pharmaceutical market. Investors will focus on subsequent regulatory disclosures and the operating performance of the acquired business.

Aurobindo Pharma at a glance

  • Company: Aurobindo Pharma Limited
  • ISIN: INE406A01037
  • NSE ticker: AUROPHARMA
  • Regulatory update: US FDA OAI classification at a Lannett facility, November 11, 2026

Aurobindo Pharma operates in the Indian market environment tracked by the BSE Sensex.

Find More news and analyses on Aurobindo Pharma stock.

Disclaimer...
en | INE406A01037 | AUROBINDO | boerse | 70538250 | bgmi